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Abstract 
Background: The mineralocorticoid receptor (MR) is expressed in the kidneys and in adipose tissue, and 
primary aldosteronism (PA) is associated with metabolic syndrome. This study assessed the effects of MR 
blockade by eplerenone and spironolactone on blood pressure and metabolic factors in patients with PA. 
Methods and Results: Fifty-four patients with PA were treated with one of two MR antagonists, eplerenone 
(25-100 mg daily, n=27) or spironolactone (12.5-100 mg daily, n=27), for 12 months. Visceral (VAT) and 
subcutaneous adipose tissue (SAT) were quantified using CT and FatScan imaging analysis software. Body 
mass index (BMI), homeostasis model assessment-insulin resistance (HOMA-IR), serum creatinine, 
potassium and lipids, urinary albumin excretion and plasma aldosterone (PAC) and PRA were measured 
before and after treatment. Eplerenone and spironolactone decreased blood pressure and increased serum 
potassium levels to similar degrees. PAC and PRA did not differ between the two groups. Although treatment 
with the MR antagonists did not change HOMA-IR or serum lipids, they significantly decreased urinary 
albumin excretion and VAT (p<0.05). 
Conclusion: These results suggest that eplerenone and spironolactone are effective and safe for the treatment 
of PA. The long-term metabolic and renal effects of these MR antagonists should be further investigated. 
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 Introduction 
Primary aldosteronism (PA) is the most common form of secondary hypertension, with an estimated 
prevalence of 5-15% in all hypertensive patients [1, 2]. Excess aldosterone has adverse cardiovascular and 
renal consequences in patients with hypertension and in patients with diabetes mellitus or chronic renal 
disease [3, 4]. We have previously reported that PA patients have a higher incidence of cardiovascular 
complications than age- and sex-matched patients with essential hypertension [5]. Several studies have shown 
that PA is common in patients with resistant hypertension, with a prevalence of approximately 20% [6], and 
PA is associated with a significant increase in risk of end-organ damage and cardiovascular events compared 
with more easily controlled hypertension [7].  
Patients with aldosterone-producing adenoma (APA) or unilateral adrenal hyperplasia are often treated with 
unilateral laparoscopic adrenalectomy. Although surgical removal of APA improves hypertension by up to 
30–50% [8], there are no data to show that adrenalectomy is superior to medical treatment. Spironolactone 
and eplerenone, which both directly antagonize the mineralocorticoid receptor (MR), are the most appropriate 
therapeutic agents in patients with PA [9]. Spironolactone has been widely used for the treatment of PA, but 
its use is limited by adverse effects such as gynecomastia, mastodynia, menstrual abnormalities and 
impotence due to androgen receptor antagonist activity. Eplerenone is a more specific MR antagonist and has 
very few side effects [4].  
Patients with PA have a significantly higher prevalence of metabolic syndrome than those with essential 
hypertension (EHT) [10, 11,12]. The mineralocorticoid receptor (MR) is expressed in the kidneys and in 
adipose tissue. Eplerenone improves obesity-related insulin resistance through the reduction of fat reactive 
oxygen species (ROS) production, inflammatory processes, and induction of cytokines in ob/ob mice. [13]. 
We examined the effects of MR blockade by eplerenone and spironolactone on blood pressure, renal function 




The protocol and informed consent form were reviewed by the appropriate Independent Ethics Committee or 
Institutional Review Board prior to enrollment of any study patients. The clinical trial registration No. was 
UMIN000004581. To be included in the trial, men and non-childbearing women were at least 18 years of age 
with hypertension (seated diastolic BP≥90 and ≤120 mmHg with systolic BP<200 mmHg), serum potassium 
more than 3.0 and less than 5.0 mmol/L. Exclusion criteria included history of accelerated/malignant 
hypertension, sex hormone therapy, reduced renal function (serum creatinine >1.5 mg/dL in men and 1.3 
mg/dL in women), liver disease based on transaminases more than two times the upper limit of normal, and a 
history of heart failure, myocardial infarction, stroke or serious cardiovascular event within 6 months. 
Fifty-four hypertensive patients (24 men and 30 women; aged 56 ± 10 years) were diagnosed with PA 
according to The Japanese Society of Endocrinology Guidelines for the Management of PA [14] in the 
Kanazawa University Hospital and two municipal hospitals. Thirty-nine patients underwent adrenal venous 
sampling (AVS); 9 subjects had unilateral aldosterone hypersecretion (4 patients in the SPL group and 5 
patients in the EPL group), and 30 subjects had bilateral production of aldosterone (17 patients in the SPL 
group and 13 patients in the EPL group). AVS was not performed in 15 patients because they did not want to 
undergo the operation (6 patients in the SPL group and 9 patients in the EPL group). 
Study Design 
This was an open-label, non-controlled study. After a 2-week washout period, patients with PA underwent 
randomization with the envelop method: 27 patients received spironolactone (25 mg) and 27 received 
eplerenone (50 mg) as the first dose. If blood pressure (BP) was not at the goal level (<140/90 mmHg) after 4 
weeks of treatment, the dose of spironolactone or eplerenone was increased up to 100 mg. If BP remained 
uncontrolled after 8 weeks, a calcium channel blocker was added. The duration of hypertension was 7.7 ± 8.9 
(eplerenone group) and 6.0 ± 8.7 years (spironolactone group). We assessed the visceral and subcutaneous fat 
area, insulin resistance as represented by HOMA-IR, lipid parameters and urine albumin excretion at baseline 
and after MR blockade treatment. The study was performed in accordance with the principles of the 
Declaration of Helsinki, and the investigational protocol was approved by the Ethics Committee for Human 
Studies at the Kanazawa University Hospital. All patients provided written informed consent. 
Laboratory Measurements 
Body mass index (BMI) was calculated as weight (kg) divided by height (cm) squared. Venous blood samples 
were obtained after a 12 h overnight fast after a 15 min rest in the supine position in the morning. Serum 
lipids, potassium, glucose, and creatinine were determined by standard procedures. HbA1c was measured by 
high-pressure liquid chromatography. Urinary albumin was measured using a commercial enzyme-linked 
immunosorbent assay (ELISA) kit. Plasma immunoreactive insulin (IRI) was measured using ELISA, and 
blood glucose was measured using the glucose oxidase method. The insulin resistance index was calculated 
based on HOMA-IR [fasting glucose (mg/dL) ×fasting insulin (mU/mL)/405]. The plasma aldosterone 
concentration (PAC), plasma renin activity (PRA) and serum cortisol concentration were measured by 
radioimmunoassay as previously reported [15]. 
Measurement of Abdominal Adipose Tissue by CT 
CT scans were performed using a 64-channel multi-detector row CT (MDCT) (GE Healthcare, Little Chalfont, 
Buckinghamshire, England). All subjects underwent CT at the umbilical level to measure the cross-sectional 
abdominal subcutaneous adipose tissue (SAT) area and visceral adipose tissue (VAT) area using FatScan 
software (N2 System Corp, Osaka, Japan) [16]. FatScan software enables multiple image rendering and 
geometric measurements of a specific region with a specified CT number (in Hounsfield units). A single 
cross-sectional scan at the level of the umbilicus was selected for quantification. Adipose tissue was 
determined by setting the attenuation level within the range of -190 to-30 Hounsfield units, and the acquired 
image corresponded to the total fat region. The region of visceral fat was defined by manual tracing of its 
contour, and the total fat region was divided into visceral and subcutaneous fat regions. Finally, the VAT was 
calculated by the software. 
Statistics 
Data are expressed as the means ± S.Ds. All of the analyses were conducted using SPSS software version 18.0 
for Windows (SPSS, Chicago, IL). Two-sided tests of treatment differences, based on analysis of covariance 
(ANOCOVA) with baseline as a covariate and treatment and center as factors were used to compare the 
effects of spironolactone and eplerenone. 
Results 
No significant differences in the clinical data were observed between the two groups (Table 1). There were 11 
metabolic syndrome patients, three diabetic patients, and fifteen dyslipidemic patients in the spironolactone 
group at baseline. There were eight metabolic syndrome patients, four diabetic patients, fourteen dyslipidemic 
patients in the eplerenone group at baseline. Additional antihypertensive drugs and other medications used at 
the end point are shown in Table 2. Two patients had successfully decreased blood pressure with 25 mg/day 
of SPL, so their dose of SPL was reduced to 12.5 mg/day; these patients maintained their target blood 
pressure. Table 3 summarizes the effects of mineralocorticoid receptor antagonists (MRAs) on BP, PAC, PRA, 
serum potassium, renal function, and serum metabolic factors. Figure 1 shows treatment with spironolactone 
or eplerenone significantly decreased systolic BP and diastolic BP (p<0.001). Serum potassium levels did not 
exceed 5.0 m Eq/L in any patients. Estimated GFR tended to decrease, but urinary albumin excretion (UAE) 
was significantly improved by MR antagonist treatment (p=0.024). The differences between the effects of 
eplerenone and spironolactone on systolic and diastolic BP, PRA, PAC, serum potassium, eGFR, UAE, and 
metabolic factors are shown in Table 3. The blood pressure lowering effects between the two agents did not 
differ. Spironolactone significantly increased PAC compared with eplerenone (p=0.007). PRA, serum 
potassium, eGFR and UAE did not differ between the two groups. The metabolic factors did not significantly 
differ between the two groups. Body weight, BMI, waist circumference, VAT and SAT area were not different 
between the two groups. Although BMI and VAT area were significantly decreased in all patients (p<0.05), 
no significant differences in BMI, VAT and SAT area were observed between the two groups. Two patients 
treated with spironolactone experienced gynecomastia. No patients treated with eplerenone showed 
gynecomastia. 
Discussion 
Spironolactone has been successfully used in the treatment with PA for more than four decades as 
monotherapy or in combination with other antihypertensive drugs [9]. Eplerenone is approved for the 
treatment of essential hypertension in the United States and Japan, but not in Europe [17]. Both eplerenone 
and spironolactone inhibit activation of the human mineralocorticoid receptor, and spironolactone is more 
potent than eplerenone in blocking the aldosterone activation of mineralocorticoid receptors [18]. Weinberger 
et al. [19] reported that the blood pressure reduction with spironolactone 50 mg b.i.d. was greater than with 
eplerenone 50 mg b.i.d. or 100 mg/day. There are limited data on the effects of eplerenone in patients with PA. 
Two recent studies compared the efficacy of eplerenone and spironolactone on blood pressure reduction in 
patients with PA. Karagiannis et al. [20] showed that treatment with eplerenone (from 50 to 200 mg/day) or 
spironolactone (from 50 to 400 mg/day) for 16 weeks in 34 patients with IHA resulted in an equally effective 
reduction in blood pressure. Parthasarathy et al. [21] reported that the antihypertensive effects of 
spironolactone (from 75 to 225 mg) were significantly greater than those of eplerenone (from 100 to 300 mg) 
in 141 patients with PA including APAs. Two studies reported the adverse events associated with 
spironolactone treatment, which included gynecomastia, breast pain in females and impotence. The early 
trials of spironolactone demonstrated its efficacy at doses up to over 200 mg, whereas lower doses of 
spironolactone have recently been used to avoid dose- and time-dependent adverse events while maintaining 
the drug’s antihypertensive effects [22, 23]. Our data with lower doses of spironolactone or eplerenone might 
be more practical. Calcium channel blockers decrease aldosterone synthesis in human adrenocortical cells 
[24] and in hypertensive patients [25]. Nakamura et al. reported that eplerenone potentiates the protective 
effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats independently of blood 
pressure [26]. In this study, 30-40% of patients needed to use amlodipine to achieve BP <140/90 mmHg. 
Other blood pressure lowering agents such as ACE inhibitors, angiotensin II receptor blockers and thiazide 
diuretics were not used. Our data suggest that calcium channel blockers are useful add-ons for the treatment 
of PA. 
Recent in vitro studies have suggested that aldosterone and the MR might influence adipocyte behavior. 
Caprio et al. [27] reported that aldosterone promotes maturation of pre-adipocytes to adipocytes in a time-, 
dose-, and MR-dependent manner. Brines et al. [28] reported that adipocytes produce aldosterone, which 
regulates adipocyte differentiation and vascular function in an autocrine and paracrine manner. In addition, a 
higher prevalence of glycemic abnormalities and of the metabolic syndrome has been demonstrated in 
patients with PA compared with those with essential hypertension [29]. Although a cause-effect relationship 
has not been established, the available evidence indicates that VAT might be a common element linking the 
many facets of the metabolic syndrome, including glucose intolerance, hypertension, dyslipidemia, and 
insulin resistance [30]. We found that treatment with MRAs decreased VAT but not SAT in patients with PA; 
however, serum lipids and HOMA-IR were not influenced by the medical treatment. Catena et al. [31] 
reported that treatment with surgery or MR antagonists rapidly and persistently restores normal sensitivity to 
insulin in patients with PA, which was independent of plasma potassium levels. In their report, HOMA-IR 
was decreased at 6 months after treatment and increased to the baseline levels over an average period of 5.7 
years. Kosmala et al. [32] reported that treatment with spironolactone in patients with metabolic syndrome 
resulted in a significant decrease in biomarkers of collagen synthesis, left atrial dimension, left ventricular 
wall thickness and mass. The beneficial effects of MR antagonists on cardiovascular and metabolic factors 
should be further investigated. 
In this study, MR blockade therapy decreased urinary albumin excretion in patients with PA. We have 
previously reported that spironolactone reduced urinary albumin excretion in diabetic patients [33]. Nagase et 
al. [34] reported that eplerenone improved podocyte damage and retarded the progression of proteinuria and 
glomerulosclerosis. Iwakura et al. showed that in 111 patients with bilateral hyperaldosteronism treated with 
mineralocorticoid receptor antagonists, urinary albumin excretion and eGFR were significantly decreased at 
12 months after treatment; these results were consistent with the results from our study [35]. Iwakura et al. 
noted that patients with higher urinary albumin excretion prior to treatment had the greatest reduction in 
eGFR. Recently, Ando et al [36] reported that the addition of low-dose eplerenone to renin-angiotensin 
system inhibitors had renoprotective effects through the reduction of albuminuria in non-diabetic hypertensive 
patients. A limitation of this current study is that in keeping with ethical practices, the study could not be 
controlled with a placebo. We did not provide enrolled subjects a special diet program to change their 
lifestyles, but the patients in both the spironolactone group and eplerenone group might have changed their 
lifestyles of their own volition. BMI decreases during treatment occurred, and lifestyles might have changed. 
Francis et al. showed that aldosterone stimulates salt appetite, and MRA administered 
intracerebroventricularly or intraperitoneally significantly reduced salt ingestion in congestive heart failure 
model rats [37]. 
Eplerenone was as effective as spironolactone for the treatment of hypertension in patients with PA and 
showed fewer side effects. The beneficial effect of both drugs on VAT is of interest and should be further 
investigated. 
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Table.1 Baseline characteristics 
 
 SPL EPL  
 （n=27） （n=27） P value 
Age(years) 56.1±9.9 54.9±10.7 0.660 
male/female 11/16 13/14  
sBP(mmHg) 157±19 150±19 0.104 
dBP(mmHg) 96±11 92±14 0.060 
s-K(mEq/l) 3.9±0.3 3.9±0.3 0.912 
PRA（ng/ml/hr） 0.3±0.3 0.4±0.3 0.322 
PAC(pg/ml) 128±55 140±60 0.424 
p-aldo/PRA ratio 602±443 470±271 0.191 
 
Data are the mean±S.D. BP, blood pressure; s-K, serum potassium PRA; plasma renin 
activity; PAC, plasma aldosterone concentration. 
  
Table 2. Antihypertensive medications used at end point and treatment for diabetes and 
dyslipidemia 
 
Mineralocorticoid receptor blocker SPL EPL 
（n = 27） （n = 27） 
Dose (mg/day) 32.4±13.1 74.1±28.1 
Range (mg/day) 12.5 – 100 25 – 100 
Period (months) 12.7±1.5 12.4±1.1 
Calcium channel blocker 9 （33.3） 11（40.7） 
α-Blocker 1 （3.7） 1（3.7） 
Treatment for diabetes mellitus 2（7.4） 4（14.8） 
Sulfonylurea 1 （3.7） 2 （7.4） 
Biguanide 1 (3.7) 1 (3.7) 
α-glucosidase inhibitors 0 （0） 1（3.7） 
Treatment for dyslipidemia 4（14.8） 3 （11.1） 
Statin 3 （11.1） 3（11.1） 
Data are the mean±S.D. Data represent number (percent). 
  
Table.3 Baseline Metabolic parameters and their changes at end of follow-up in the 
whole patients, SPL group and EPL group 
 
ALL SPL EPL 
 
Baseline End of study Baseline End of study Baseline End of study 
Systolic BP (mmHg) 153±19 125±12‡ 157±19 127±11‡ 150 ±19 122±14‡ 
Diastolic BP (mmHg) 95±12 77±10‡ 96±11 77±8‡ 92±14 76±12‡ 
PRA （ng/ml/hr） 0.4±0.3 1.3±1.1‡ 0.3±0.3 1.5±1.3‡ 0.4±0.3 1.1±1.0‡ 
PAC (pg/ml) 135±57 213±90‡ 128±55 244±84‡ 140±60 184±88
＊
 





serum-Potassium(mEq/l) 3.9±0.4 4.2±0.3‡ 3.9±0.3 4.3±0.3‡ 3.9±0.3 4.2±0.3† 
eGFR (ml/min/1.73m
2
) 79.9±18.6 74.4±18.0 78.5±18.5 72.5±20.6‡ 81.3±18.9 76.3±15.2
＊
 
UAE (mg/gCr) 10.4 (5.8-21.9) 6.3 (4.5-15.9)
＊
 10.0 (5.6-21) 5.6 (4.2-15.4) 10.8(5.3-22.4) 7.0 (4.8-16.4) 
Fasting plasma glucose (mg/dl) 103±17 104±19 106±21 107±23 99±12 100±13 
Plasma insulin 5.6 (4.4-11.0) 6.5 (4.7-9.4) 7.2 (4.2-11.3) 8.1(4.0-9.9) 7.5 (4.4-9.1) 6.5 (5.3-8.0) 
HOMA-IR 1.3 (1.0-2.7) 1.5 (1.1-2.4) 1.8(1.0-3.0) 2.1(1.0-2.8) 1.3 (1.1-2.2) 1.5 (1.2-2.1) 
HOMA-β 60（44-108） 70 (47-93) 63(39-105) 62(44-82) 57 (46-109) 76 (48-99) 
HbA1c (%) 5.3±1.0 5.2±1.2 5.5±0.6 5.1±1.7 5.0±1.2 5.3±0.6 
Triglycerides (mg/dl) 109 (76-168) 104 (67-155) 114(81-180) 109(71-161) 106 (74-134) 98 (62-153) 
HDL-C (mg/dl) 55±15 54±17 56±17 55±20 53±14 53±13 
LDL-C (mg/dl) 117±32 110±30 117±25 110±33 117±37 111±27 
Body Weight (kg) 64.4±13.0 63.5±12.8 63.2±12.2 62.5±13.1 65.6±13.8 64.4±12.7 




 24.2±2.6 23.6±3.1 24.9±3.3 24.4±2.8 
Waist circumstance (cm) 85.7±9.1 85.2±9.0 84.2±8.9 84.3±9.9 86.5±9.3 85.6±8.7 




 96.6±54.5 85.8±54.2 93.6±47.1 90.0±50.5 
Subcutaneous fat area (cm
2
) 162.0±63.0 157.3±58.5 145.2±48.0 137.4±44.9 170.1±68.5 166.9±65.6 
（mean±S.D.） ‡; p<0.001,  †; P<0.01, ＊; P<0.05, a ;vs EPL group p<0.001 
